Market Overview

Wall Street Analysts Give A Resounding 'Buy!' On AC Immune

Share:
Wall Street Analysts Give A Resounding 'Buy!' On AC Immune
Related
Experts React To Concerning Alzheimer's News From Eli Lilly
Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

AC Immune Ltd (NASDAQ: ACIU) has attracted Wall Street analysts' attention on Tuesday after more than three weeks since its 6.0 million IPO. Significantly, three brokerages have accorded a Buy or an Outperform rating on the stock.

AC Immune, which is a clinical stage biopharmaceutical firm, came out with its IPO in September. The company priced its IPO at $11.00 a share on September 22 and opened with 28 percent gain on the following day. The stock has traded between $13.01 and $19.97 since then.

Until now, the stock has already delivered more than 35 percent returns. Based on the three brokerage's least target price of $18, there is still upside potentials of about 18 percent. Similarly, the highest price objective of $25 reflected a possible upside of more than 60 percent.

Related Link: AC Immune Is An Alzheimer's Pure Play With A Lot On The Line

The following are the ratings and price objectives assigned by brokerages:

  • Credit Suisse initiated with an Outperform rating with $18 as the price objective.
  • Jefferies started with a Buy rating with a price target of $25.
  • Leerink Swan commenced with an Outperform rating and a target price of $22.

At last check, AC Immune was up 5.47 percent at $15.22.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for ACIU

DateFirmActionFromTo
Oct 2016Leerink SwannInitiates Coverage OnOutperform
Oct 2016Credit SuisseInitiates Coverage OnOutperform
Oct 2016JefferiesInitiates Coverage OnBuy

View More Analyst Ratings for ACIU
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Initiation Analyst Ratings Best of Benzinga

 

Related Articles (ACIU)

View Comments and Join the Discussion!